SAN DIEGO, Aug. 18 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, today announced that it has entered into an agreement with GVK Biosciences (GVK BIO) to expand the opportunity for Aethlon to commercialize its Hemopurifier® treatment technology at three to five new clinical centers in India. The therapeutic focus at each center will be the implementation of the Hemopurifier® as an adjunct therapy to accelerate the benefit of HCV standard of care (SOC) drug regimens. Therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with patients most likely to achieve a sustained viral response, which is the goal of HCV therapy. GVK BIO is Asia's leading Discovery Research and Development organization.
Aethlon further disclosed that the Ethics Review Board (ERB) at Medanta, The Medicity Institute (Medicity) met on August 14th, 2010 to discuss the potential approval for Aethlon to initiate HCV treatment programs at the Medicity. Aethlon has been advised that a formal response should be expected from the Medicity ERB in the coming weeks. The Medicity is a $360 million facility recently established on a 43-acre campus to be a premier center of medical tourism in India.
About GVK BiosciencesGVK Biosciences (GVK BIO) is Asia's
leading Discovery Research and Development organization. GVK BIO
provides a broad spectrum of services, stand-alone and integrated,
across the R&D value chain. '/>"/>